{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:51:47Z","timestamp":1793400707007,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10928-025-09988-1","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T21:33:40Z","timestamp":1753738420000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lessons learned from QT prolongation risk assessment for antibody-drug conjugates in oncology"],"prefix":"10.1007","volume":"52","author":[{"given":"Shruti D","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanne C","family":"Jewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Ferron-Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra A.G.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"issue":"1","key":"9988_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","volume":"23","author":"K Liu","year":"2024","unstructured":"Liu K et al (2024) A review of the clinical efficacy of FDA-approved antibody\u2013drug conjugates in human cancers. Mol Cancer 23(1):62","journal-title":"Mol Cancer"},{"key":"9988_CR2","doi-asserted-by":"publisher","first-page":"e390094","DOI":"10.1200\/EDBK_390094","volume":"43","author":"M Shastry","year":"2023","unstructured":"Shastry M et al (2023) Rise of Antibody-Drug conjugates: the present and future. Am Soc Clin Oncol Educ Book 43:e390094","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"8","key":"9988_CR3","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/d41573-024-00064-w","volume":"23","author":"P Flynn","year":"2024","unstructured":"Flynn P et al (2024) The antibody-drug conjugate landscape. Nat Rev Drug Discov 23(8):577\u2013578","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"9988_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama K et al (2024) Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol 21(3):203\u2013223","journal-title":"Nat Rev Clin Oncol"},{"key":"9988_CR5","doi-asserted-by":"crossref","unstructured":"Gogia P et al (2023) Antibody-Drug conjugates: A review of approved drugs and their clinical level of evidence. Cancers (Basel), 15(15).","DOI":"10.3390\/cancers15153886"},{"key":"9988_CR6","doi-asserted-by":"crossref","unstructured":"Tong JTW et al (2021) An insight into FDA approved Antibody-Drug conjugates for Cancer therapy. Molecules, 26(19)","DOI":"10.3390\/molecules26195847"},{"key":"9988_CR7","unstructured":"International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. Fed Regist 70(202):61134\u20135"},{"key":"9988_CR8","unstructured":"International Conference on Harmonisation (ICH): E14 Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs \u2014 Questions and Answers (R3) Guidance for Industry. (2017) Accessed October 28 2024; Available from: https:\/\/www.fda.gov\/media\/71372\/download"},{"key":"9988_CR9","unstructured":"International Conference on Harmonisation (ICH): E14 and S7B Clinical and Nonclinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential\u2013Questions and Answers. (2022) Accessed October 28 2024; Available from: https:\/\/www.fda.gov\/media\/161198\/download"},{"issue":"3","key":"9988_CR10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","volume":"45","author":"C Garnett","year":"2018","unstructured":"Garnett C et al (2018) Scientific white paper on concentration-QTc modeling. J Pharmacokinet Pharmacodyn 45(3):383\u2013397","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9988_CR11","unstructured":"Clinical Pharmacology Considerations for Antibody-Drug Conjugates, Guidance for Industry. (2024) Accessed October 28 2024; Available from: https:\/\/www.fda.gov\/media\/155997\/download"},{"issue":"9","key":"9988_CR12","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1634\/theoncologist.2017-0604","volume":"23","author":"KJ Norsworthy","year":"2018","unstructured":"Norsworthy KJ et al (2018) FDA approval summary: Mylotarg for treatment of patients with relapsed or refractory CD33-Positive acute myeloid leukemia. Oncologist 23(9):1103\u20131108","journal-title":"Oncologist"},{"key":"9988_CR13","unstructured":"Besponsa (inotuzumab ozogamicin) prescribing information (USPI); Reference ID: 4140675. (2017) Accessed October 28 2024; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761040s000lbl.pdf"},{"key":"9988_CR14","unstructured":"Mylotarg (gemtuzumab ozogamicin) CDER summary review. (2017) Accessed October 28 2024; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761060Orig1s000Orig1Orig2s000SumR.pdf"},{"key":"9988_CR15","unstructured":"ADC Review; Belantamab mafodotin (Blenrep). Available from: https:\/\/www.adcreview.com\/drugmap\/belantamab-mafodotin-blenrep-gsk2857916-j6m0-mcmmaf\/"},{"key":"9988_CR16","unstructured":"Adcetris (brentuximab vedotin) prescribing information (USPI); Reference ID: 3662552. (2011) October 28 2024; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125388s000,125399s000lbl.pdf"},{"key":"9988_CR17","unstructured":"Polivy (polatuzumab vedotin-piiq) prescribing information (USPI); Reference ID: 4446006. (2019) Accessed October 28 2024; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761121s000lbl.pdf"},{"key":"9988_CR18","unstructured":"Padcev (enfortumab vedotin-ejfv) prescribing information (USPI); Reference ID: 4536404. (2019) Accessed October 28 2024; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761137s000lbl.pdf"},{"key":"9988_CR19","unstructured":"BLENREP (belantamab mafodotin-blmf) prescribing information (USPI); Reference ID: 4652412. (2020) Accessed October 28 2024; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761158s000lbl.Pdf"},{"key":"9988_CR20","unstructured":"Kadcyla (ado-trastuzumab emtansine) prescribing information (USPI); Reference ID: 4428535. (2013) October 28 2024; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125427lbl.pdf"},{"key":"9988_CR21","unstructured":"Elahere (mirvetuximab soravtansine-gynx) prescribing information (USPI); Reference ID: 5077370. (2022) Accessed October 28 2024; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761310s000lbl.pdf"},{"key":"9988_CR22","unstructured":"Elahere (mirvetuximab soravtansine-gynx) multi-discipline review 761310Orig1s000 (2022) Accessed October 28 2024; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/761310Orig1s000MultidisciplineR.pdf"},{"key":"9988_CR23","unstructured":"Oncolive (2023): AstraZeneca to Discontinue Moxetumomab Pasudotox in US for Hairy Cell Leukemia. Accessed October 28 2024; Available from: https:\/\/www.onclive.com\/view\/astrazeneca-to-discontinue-moxetumomab-pasudotox-in-us-for-hairy-cell-leukemia"},{"key":"9988_CR24","unstructured":"Lumoxiti (moxetumomab pasudotox-tdfk) CDER Multidisciplinary Review 761104Orig1s000. (2018) Accessed October 28 2024; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/761104Orig1s000MultidisciplineR.pdf"},{"key":"9988_CR25","unstructured":"Enhertu (fam-trastuzumab deruxtecan-nxki) prescribing information (USPI); Reference ID: 4537820. (2019) Accessed October 28 2024; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761139s000lbl.pdf"},{"key":"9988_CR26","unstructured":"Datroway\u00ae (datopotamab deruxtecan-dlnk) prescribing information (USPI); Reference ID: 5513870. (2025); Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761394s000lbl.pdf"},{"key":"9988_CR27","unstructured":"Trodelvy Trodelvy (sacituzumab govitecan-hziy) prescribing information (USPI); Reference ID: 4596074. (2020) Accessed October 28 2024; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761115s000lbl.pdf"},{"key":"9988_CR28","unstructured":"Trodelvy (sacituzumab govitecan-hziy) CDER Multidiscipline review 761115Orig1s000. (2020) Accessed October 28 2024; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/761115Orig1s000MultidisciplineR.pdf"},{"key":"9988_CR29","unstructured":"Zynlonta (loncastuximab tesirine-lpyl) prescribing information (USPI); Reference ID: 4784313. (2021) Accessed October 28 2024; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761196s000lbl.pdf"},{"key":"9988_CR30","unstructured":"Zynlonta (loncastuximab tesirine-lpyl) CDER Multi-discipline review 761196Orig1s000. (2021) Accessed October 28 2024; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/761196Orig1s000MultidisciplineR.pdf"},{"key":"9988_CR31","unstructured":"International Conference on Harmonisation (ICH): Guidance for Industry S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals 2005; Available from: https:\/\/www.fda.gov\/media\/72043\/download"},{"key":"9988_CR32","unstructured":"Enhertu multidiscipline review 761139Orig1s000. (2019) Accessed October 28 2024; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761139Orig1s000MultidisciplineR.pdf"},{"issue":"2","key":"9988_CR33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.vascn.2008.04.001","volume":"58","author":"HM Vargas","year":"2008","unstructured":"Vargas HM et al (2008) Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. J Pharmacol Toxicol Methods 58(2):72\u201376","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"6","key":"9988_CR34","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/cpt.3047","volume":"114","author":"WW Wu","year":"2023","unstructured":"Wu WW et al (2023) ICH S7B in vitro assays do not address mechanisms of QT(C) prolongation for peptides and Proteins - Data in support of not needing dedicated QT(C) studies. Clin Pharmacol Ther 114(6):1332\u20131341","journal-title":"Clin Pharmacol Ther"},{"key":"9988_CR35","unstructured":"International Conference on Harmonisation (ICH): E14 Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. (2005) Accessed October 28 2024; Available from: https:\/\/www.fda.gov\/media\/71372\/download"},{"key":"9988_CR36","unstructured":"Datroway\u00ae (datopotamab deruxtecan-dlnk) multi-discipline review 761394Orig1s000. (2025); Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2025\/761394Orig1s000MultidisciplineR.pdf"},{"key":"9988_CR37","unstructured":"Datroway\u00ae (datopotamab deruxtecan-dlnk) Other review 761394Orig1s000 2025. (2025) [cited 2025; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2025\/761394Orig1s000OtherR.pdf"},{"issue":"10","key":"9988_CR38","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1016\/j.hrthm.2017.10.035","volume":"15","author":"SM Al-Khatib","year":"2018","unstructured":"Al-Khatib SM et al (2018) 2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: A report of the American college of cardiology\/american heart association task force on clinical practice guidelines and the heart rhythm society. Heart Rhythm 15(10):e190\u2013e252","journal-title":"Heart Rhythm"},{"issue":"8","key":"9988_CR39","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/jcph.1844","volume":"61","author":"S Cohen-Rabbie","year":"2021","unstructured":"Cohen-Rabbie S et al (2021) QT prolongation risk assessment in oncology: lessons learned from Small-Molecule new drug applications approved during 2011\u20132019. J Clin Pharmacol 61(8):1106\u20131117","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"9988_CR40","doi-asserted-by":"publisher","first-page":"705","DOI":"10.5414\/CP202337","volume":"53","author":"T Jackson","year":"2015","unstructured":"Jackson T, Kondic J, Seebeck J (2015) QT-prolonging effects of monoclonal antibody drugs in humans: a systematic review of two literature and a public adverse event database. Int J Clin Pharmacol Ther 53(9):705\u2013711","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"6","key":"9988_CR41","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00280-021-04250-0","volume":"87","author":"SN Liu","year":"2021","unstructured":"Liu SN, Li C (2021) Clinical Pharmacology strategies in supporting drug development and approval of antibody-drug conjugates in oncology. Cancer Chemother Pharmacol 87(6):743\u2013765","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"9988_CR42","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1016\/S1470-2045(22)00221-2","volume":"23","author":"EL Giraud","year":"2022","unstructured":"Giraud EL et al (2022) The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview. Lancet Oncol 23(9):e406\u2013e415","journal-title":"Lancet Oncol"},{"issue":"5","key":"9988_CR43","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00280-017-3284-y","volume":"79","author":"WP Munasinghe","year":"2017","unstructured":"Munasinghe WP et al (2017) Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR. Cancer Chemother Pharmacol 79(5):915\u2013922","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"9988_CR44","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/cts.12928","volume":"14","author":"JW Goldman","year":"2021","unstructured":"Goldman JW et al (2021) Effects of rovalpituzumab Tesirine on ventricular repolarization in patients with Small-Cell lung Cancer. Clin Transl Sci 14(2):664\u2013670","journal-title":"Clin Transl Sci"},{"issue":"2","key":"9988_CR45","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/cpt.2029","volume":"109","author":"HM Vargas","year":"2021","unstructured":"Vargas HM et al (2021) Time for a fully integrated Nonclinical-Clinical risk assessment to streamline QT prolongation liability determinations: A pharma industry perspective. Clin Pharmacol Ther 109(2):310\u2013318","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"9988_CR46","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/cpt.3219","volume":"116","author":"MM Abernathy","year":"2024","unstructured":"Abernathy MM, Leishman DJ (2024) The efficacy, effectiveness, and efficiency of integrated QTc assessment: rationalizing approaches to new drug modalities. Clin Pharmacol Ther 116(1):22\u201325","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"9988_CR47","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/cpt.3204","volume":"116","author":"Y Qu","year":"2024","unstructured":"Qu Y et al (2024) Scientific review of the proarrhythmic risks of oligonucleotide therapeutics: are dedicated ICH S7B\/E14 studies needed for Low-Risk modalities?? Clin Pharmacol Ther 116(1):96\u2013105","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"9988_CR48","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00280-023-04516-9","volume":"91","author":"P Montesinos","year":"2023","unstructured":"Montesinos P et al (2023) A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of Gemtuzumab Ozogamicin in patients with relapsed\/refractory CD33-positive acute myeloid leukemia. Cancer Chemother Pharmacol 91(5):441\u2013446","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"9988_CR49","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00280-013-2192-z","volume":"72","author":"TH Han","year":"2013","unstructured":"Han TH et al (2013) Brentuximab Vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies. Cancer Chemother Pharmacol 72(1):241\u2013249","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"9988_CR50","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/cpdd.9","volume":"2","author":"M Gupta","year":"2013","unstructured":"Gupta M et al (2013) Effects of trastuzumab emtansine (T-DM1) on QT interval and safety of Pertuzumab plus T-DM1 in patients with previously treated human epidermal growth factor receptor 2-Positive metastatic breast Cancer. Clin Pharmacol Drug Dev 2(1):11\u201324","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"3","key":"9988_CR51","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/bcp.13832","volume":"85","author":"JE Hibma","year":"2019","unstructured":"Hibma JE et al (2019) Effect of inotuzumab Ozogamicin on the QT interval in patients with haematologic malignancies using QTc-concentration modelling. Br J Clin Pharmacol 85(3):590\u2013600","journal-title":"Br J Clin Pharmacol"},{"key":"9988_CR52","doi-asserted-by":"publisher","first-page":"115193","DOI":"10.1016\/j.addr.2024.115193","volume":"207","author":"MZ Liao","year":"2024","unstructured":"Liao MZ et al (2024) Clinical Pharmacology strategies to accelerate the development of polatuzumab Vedotin and summary of key findings. Adv Drug Deliv Rev 207:115193","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"9988_CR53","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/cpt.2757","volume":"113","author":"A Shimomura","year":"2023","unstructured":"Shimomura A et al (2023) Effect of trastuzumab Deruxtecan on qt\/qtc interval and pharmacokinetics in HER2-Positive or HER2-Low metastatic\/unresectable breast Cancer. Clin Pharmacol Ther 113(1):160\u2013169","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"9988_CR54","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1111\/bcp.16133","volume":"90","author":"RC Jewell","year":"2024","unstructured":"Jewell RC et al (2024) Belantamab Mafodotin concentration-QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM-1 and\u2013\u20092 studies. Br J Clin Pharmacol 90(10):2571\u20132581","journal-title":"Br J Clin Pharmacol"},{"key":"9988_CR55","unstructured":"ADC Therapeutics S.A.: Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL). NCT03589469 (2019). Accessed October 28 2024; Available from: https:\/\/cdn.clinicaltrials.gov\/large-docs\/69\/NCT03589469\/Prot_000.pdf"},{"key":"9988_CR56","unstructured":"Tivdak (2021) (Tisotumab vedotin-tftv) multi-disciplinary review 761208Orig1s000. Accessed October 28 2024; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/761208Orig1s000MultidisciplineR.pdf"},{"issue":"23","key":"9988_CR57","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore KN et al (2023) Mirvetuximab Soravtansine in FRalpha-Positive, Platinum-Resistant ovarian Cancer. N Engl J Med 389(23):2162\u20132174","journal-title":"N Engl J Med"},{"key":"9988_CR58","unstructured":"Daiichi Sankyo Co., Ltd.: First-inhuman Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor1) NCT03401385 (2024); Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT03401385?tab=table"},{"key":"9988_CR59","unstructured":"Rashid J, JH, Benner R, Bousset P, Vandendries E, Chen Y (2023) Concentration-QT modeling analysis of gemtuzumab ozogamicin following fractionated dosing regimen in adult patients with relapsed or refractory acute myeloid leukemia. Clin Pharmacol Ther 113(S1):S5\u2013S100"},{"issue":"4","key":"9988_CR60","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40262-024-01369-0","volume":"63","author":"M Tang","year":"2024","unstructured":"Tang M et al (2024) Clinical Pharmacology of the Antibody-Drug conjugate enfortumab Vedotin in advanced urothelial carcinoma and other malignant solid tumors. Clin Pharmacokinet 63(4):423\u2013438","journal-title":"Clin Pharmacokinet"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-025-09988-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-025-09988-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-025-09988-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:45:29Z","timestamp":1757310329000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-025-09988-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["9988"],"URL":"https:\/\/doi.org\/10.1007\/s10928-025-09988-1","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"24 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors, SDS, RCJ, GFB are employees of GSK and own GSK stocks, author SAGV is employee of Alltrna and owns Alltrna stocks.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}